Cargando…

Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing

The field of lentiviral vector (LV) production continues to face challenges in large-scale manufacturing, specifically regarding producing enough vectors to meet the demand for treating patients as well as producing high and consistent quality of vectors for efficient dosing. Two areas of interest a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Michelle Yen, Kamen, Amine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237754/
https://www.ncbi.nlm.nih.gov/pubmed/35774066
http://dx.doi.org/10.3389/fbioe.2022.887716
_version_ 1784736867906748416
author Tran, Michelle Yen
Kamen, Amine A.
author_facet Tran, Michelle Yen
Kamen, Amine A.
author_sort Tran, Michelle Yen
collection PubMed
description The field of lentiviral vector (LV) production continues to face challenges in large-scale manufacturing, specifically regarding producing enough vectors to meet the demand for treating patients as well as producing high and consistent quality of vectors for efficient dosing. Two areas of interest are the use of stable producer cell lines, which facilitates the scalability of LV production processes as well as making the process more reproducible and robust for clinical applications, and the search of a cell retention device scalable to industrial-size bioreactors. This manuscript investigates a stable producer cell line for producing LVs with GFP as the transgene at shake flask scale and demonstrates LV production at 3L bioreactor scale using the Tangential Flow Depth Filtration (TFDF) as a cell retention device in perfusion mode. Cumulative functional yields of 3.3 x 10(11) and 3.9 x 10(11) transducing units were achieved; the former over 6 days of LV production with 16.3 L of perfused media and the latter over 4 days with 16 L. In comparing to a previously published value that was achieved using the same stable producer cell line and the acoustic filter as the perfusion device at the same bioreactor scale, the TFDF perfusion run produced 1.5-fold higher cumulative functional yield. Given its scale-up potential, the TFDF is an excellent candidate to be further evaluated to determine optimized conditions that can ultimately support continuous manufacturing of LVs at large scale.
format Online
Article
Text
id pubmed-9237754
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92377542022-06-29 Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing Tran, Michelle Yen Kamen, Amine A. Front Bioeng Biotechnol Bioengineering and Biotechnology The field of lentiviral vector (LV) production continues to face challenges in large-scale manufacturing, specifically regarding producing enough vectors to meet the demand for treating patients as well as producing high and consistent quality of vectors for efficient dosing. Two areas of interest are the use of stable producer cell lines, which facilitates the scalability of LV production processes as well as making the process more reproducible and robust for clinical applications, and the search of a cell retention device scalable to industrial-size bioreactors. This manuscript investigates a stable producer cell line for producing LVs with GFP as the transgene at shake flask scale and demonstrates LV production at 3L bioreactor scale using the Tangential Flow Depth Filtration (TFDF) as a cell retention device in perfusion mode. Cumulative functional yields of 3.3 x 10(11) and 3.9 x 10(11) transducing units were achieved; the former over 6 days of LV production with 16.3 L of perfused media and the latter over 4 days with 16 L. In comparing to a previously published value that was achieved using the same stable producer cell line and the acoustic filter as the perfusion device at the same bioreactor scale, the TFDF perfusion run produced 1.5-fold higher cumulative functional yield. Given its scale-up potential, the TFDF is an excellent candidate to be further evaluated to determine optimized conditions that can ultimately support continuous manufacturing of LVs at large scale. Frontiers Media S.A. 2022-06-14 /pmc/articles/PMC9237754/ /pubmed/35774066 http://dx.doi.org/10.3389/fbioe.2022.887716 Text en Copyright © 2022 Tran and Kamen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Bioengineering and Biotechnology
Tran, Michelle Yen
Kamen, Amine A.
Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing
title Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing
title_full Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing
title_fullStr Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing
title_full_unstemmed Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing
title_short Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing
title_sort production of lentiviral vectors using a hek-293 producer cell line and advanced perfusion processing
topic Bioengineering and Biotechnology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237754/
https://www.ncbi.nlm.nih.gov/pubmed/35774066
http://dx.doi.org/10.3389/fbioe.2022.887716
work_keys_str_mv AT tranmichelleyen productionoflentiviralvectorsusingahek293producercelllineandadvancedperfusionprocessing
AT kamenaminea productionoflentiviralvectorsusingahek293producercelllineandadvancedperfusionprocessing